Clinical Research Directory

Inclusion Criteria: * The general condition of the patients must be sufficient for multimodal treatment (corresponding to WHO status 0-2) * Tumordisease in a palliative setting of the following 6 groups: 1. Malignant melanoma, treatment-naive stage IV with multiple metastases and missing BRAF-V600 mutation. With indication for initiation of immunotherapy using PD-1 and CTLA-4 antibody therapy. 2. Patients with metastatic or inoperable pancreatic cancer, who are planning first-line chemotherapy with FOLFIRINOX is. 3. Patients with an indication for palliative radiation therapy extracranial, tumor manifestation with a prescribed radiation dose of 30 to 36 Gy due to hormone receptor-positive carcinoma of the breast, patients must have at least one additional (marker) lesion not treated with radiation. 4. Patients with metastatic high-grade sarcoma for whom metastasis-directed ablative therapy methods are not possible and palliative first-line therapy with doxorubicin. 5. Patients with metastatic or loco-regionally recurrent HPV-associated squamous cell carcinoma (of the head and neck region, cervix, anus or vulva) for whom local therapies are not possible and for whom palliative first-line therapy containing platinum is planned. 6. Patients with metastatic, castration-resistant prostate cancer, with progressive disease after exceeding the recommended therapy options for which a therapy attempt with lutetium-177-PSMA was indicated. Exclusion Criteria: * Presence of contraindications to simultaneous chemotherapy or whole-body hyperthermia * Serious or active comorbidities that could interfere with treatment or understanding of the nature and content of the study, for example: * Chronic inflammatory bowel disease * Acute infections * Serious cardiovascular or pulmonary comorbidities * Mental illnesses, showing the proper Study participation or recording the nature of the study to make impossible * Presence of cerebral metastasis * Diabetes mellitus with risk of end-organ damage